Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 07:15PM GMT
Release Date Price: $22.65 (+3.61%)
Dave Praharaj

All right. Good morning, everyone, and welcome to day 2 of the 41st Annual JPMorgan Healthcare Conference. My name is Dave Praharaj, and I'm an associate with the JPM Healthcare Group. Today, I have the pleasure of introducing REGENXBIO, along with their President and CEO, Ken Mills, who will be giving the presentation.

After the presentation, there will be some time for Q&A. So thank you, and take it away, Ken.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Thank you, Dave. Thanks to the JPMorgan organizers. I especially want to acknowledge [John Whittaker,] on the banking team, who's always a strong advocate for REGENXBIO at this conference and in general. Making reference here to the fact that I probably will make some forward-looking statements during the presentation today and additional information about any statements I may make or information to back them up can be found in our SEC Regulatory filings.

So I'm going to start the presentation out today with just a quick story. I have a colleague, a colleague

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot